Back to search
FDAFDA · Food and drugs·Recall number D-0376-2021

Methylprednisolone Acetate Injectable Suspension USP, 40 mg/mL, 10 mL Multiple Dose Vial, Rx Only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454 NDC 0703-0045-01

Published May 26, 2021 · Recall initiated: April 26, 2021

Summary

FDA records drug Class II recall D-0376-2021, published May 26, 2021 and initiated April 26, 2021. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 7,564/1 multiple dose vial per carton; Lot: Lot # 31327989B, exp. date 04/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Product was distributed nationwide.
Lot
Lot # 31327989B, exp. date 04/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Methylprednisolone Acetate Injectable Suspension USP, 40 mg/mL, 10 mL Multiple Dose Vial, Rx Only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454 NDC 0703-0045-01 recalled?

Yes. FDA published recall D-0376-2021 on May 26, 2021. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter